From personal struggles to public governance issues, Eli Lilly China's President publishes a signed article revealing the economic burden of obesity.

News Report (Reporter Liang Aonan): If a disease is spreading rapidly but is long considered a “personal issue,” what price will society pay? This is the core question that the concept of “Cost of Inaction” aims to answer. Regarding obesity, this issue is becoming increasingly urgent.

Recently, a set of data brought the “Cost of Inaction” into the public eye. Eli Lilly China’s president published an article titled “Lifting the Silence on the Weight of Obesity,” which mentioned that by 2025, China’s total economic cost of overweight and obesity will reach 1 trillion yuan, with nearly 60% of that coming from indirect losses such as workplace absenteeism, productivity loss, and talent drain.

Against this backdrop, Eli Lilly China has taken action by announcing that weight management medications will be officially included in the company’s employee benefits system, reimbursing prescription drug costs for colleagues who meet the criteria for obesity treatment. This initiative is based on the logic of “early intervention,” providing standardized medical support in the early stages of the disease to reduce long-term health and productivity risks. From a corporate perspective, continuous investment in scientific progress and employee health is part of long-term thinking.

The article states that at the upcoming China Development High-Level Forum, Eli Lilly will submit policy recommendations based on health economics models, urging the prevention and control of obesity to be moved upstream, shifting resource allocation from expensive comorbidity treatments to early risk management.

For a long time, overweight and obesity have been simplistically attributed to personal lifestyle choices, misunderstood as failures of self-discipline. In fact, the medical community has long agreed that obesity is a chronic, recurrent disease closely related to over 200 other conditions, including type 2 diabetes and cardiovascular diseases. When interventions are repeatedly delayed, the disease burden accumulates in more covert and costly ways, ultimately transforming into pressure on healthcare systems, workforce loss, and social productivity decline.

This is a typical path of the “Cost of Inaction”: controllable health risks in early stages turn into long-term chronic disease burdens, eventually evolving into societal costs.

Obesity is no longer just a personal health concern but a public health issue that requires systemic response. Therefore, discussions about the “Cost of Inaction” are not only a review of existing losses but also a warning about future risks.